@article{2cce19705bdf4e11bee17cdd0034bd3d,
title = "Treat early, treat appropriately",
abstract = "The treatment of type 2 diabetes is shifting from secondary specialist centres to the primary care setting. However, for this shift to be sustainable and successful, primary care physicians (PCPs) must effectively provide aspects of diabetes care traditionally supplied by specialists. In particular, the early and appropriate use of insulin in type 2 diabetes will increasingly become the responsibility of PCPs. This review examines how patients with type 2 diabetes are currently managed across several European countries, and explores the evidence around insulin use in type 2 diabetes and the implications for primary care. 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd.. All rights reserved.",
keywords = "Basal insulin, Control, Diabetes, Insulin initiation, Primary care",
author = "Andreas Liebl and Guy Rutten and Carlos Abraira",
note = "Funding Information: All authors have been involved throughout the development of the manuscripts, from initial concept to providing final approval. The meeting upon which the manuscripts in this supplement are based was funded by Novo Nordisk. Novo Nordisk was involved in the selection of faculty for this meeting, who were paid an honorarium for speaking. Medical writing assistance was provided by Eleanor Steele at Complete HealthVizion; this assistance was funded by Novo Nordisk, who also had a role in review of the manuscripts for scientific accuracy. Funds to meet journal costs for the publication of this supplement were provided by Novo Nordisk. Funding Information: Andreas Liebl has received honoraria for presentations from Eli Lilly, MSD, Roche, and Novo Nordisk, and a member of advisory boards for Eli Lilly, MSD, Roche, and Novo Nordisk. Guy Rutten has received funding for research from Novo Nordisk, Pfizer, GlaxoSmithKline, Merck Sharp & Dohme and sanofi-aventis, has acted as a consultant for Novo Nordisk, GlaxoSmithKline, Merck Sharp & Dohme and sanofi-aventis and has received honoraria for speaking from Pfizer, Novo Nordisk, Merck Sharp & Dohme and sanofi-aventis. Carlos Abraira received funding for research from GlaxoSmithKline, sanofi-aventis, Novo Nordisk, the American Diabetes Association and NIH Eye Institute, in kind grants from GlaxoSmithKline, Novo Nordisk, Kos Pharmaceuticals, and Amylin Laboratories, and lecture fees from sanofi-aventis (Visiting Professor), Takeda (Visiting Scholar) all in 2008. Publisher Copyright: {\textcopyright} 2010 Primary Care Diabetes Europe Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2010",
month = apr,
doi = "10.1016/S1751-9918(10)60003-4",
language = "English (US)",
volume = "4",
pages = "S3--S10",
journal = "Primary Care Diabetes",
issn = "1751-9918",
publisher = "Elsevier BV",
}